Lightcalls.com
 

An ancient Native American treatmen...

An ancient Native American treatment for cancer has been shown to have more [i]or[/i] less beneficial effect on tumor size, despite long-standing skepticism from the medical establishment.

Chaparral is an evergreen forsaken shrub used by native personss to treat cancer, colds, anguishs bronchitis, warts and ringworm.

Chaparral tea was widely used in the United States as an alternative anticancer agent from the late 1950 to the 1970 further the American Cancer Society said there was no essay it was an effective treatment for cancer--or for any other disease. And the US diet and Drug Administration warned against its use after research showed it could damage the liver and the kidneys.

Now, early comes from a new study that were instanted August 11 at an International interview on Head and Neck Cancer in Washington, DC present to view that an extract of the bush appears to be safe; further, it may have a positive power Researchers at the Medical University of southern Carolina have shown that an extract of chaparral may shrink an tumors.

These consequence s are not conclusive, but scientists now plan a larger application of mind aimed at showing whether the chaparral physic really does work.



The idea that plant mixs can be a source of anticancer agents is not modern For example, the drugs vinblastine and vincristine--which follow from the periwinkle plant--are used to treat many different cancers. And the medicine Taxol--obtained from the bark of yew trees--is used to treat ovarian and breast cancer.

Coincidentally, a Spanish application of mind has shown that an extract of cannabis--or marijuana--may finally be the long-sought agent that can target brain cancer small rooms Malignant brain cells have the unusual ability to evade destruction at radiotherapy, chemotherapy and surgery. however marijuana compounds called cannabinoids could starve tumors to death by way of halting the growth of line vessels that feed them. The marijuana research was published in the August 2004 issue of Cancer Research.

COPYRIGHT 2004 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved

COPYRIGHT 2004 Gale Group



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.